Research Hotspots and Frontiers of Immunotherapy for Prostate Cancer: A Visual Analysis

JIN Tongtong; ZHOU Chuan; WANG Chao; DA Zijian; ZHOU Fenghai

doi:10.3971/j.issn.1000-8578.2022.21.1486

Cancer Research on Prevention and Treatment > 2022 > 49(7): 667-674. > DOI: 10.3971/j.issn.1000-8578.2022.21.1486

JIN Tongtong, ZHOU Chuan, WANG Chao, DA Zijian, ZHOU Fenghai. Research Hotspots and Frontiers of Immunotherapy for Prostate Cancer: A Visual Analysis[J]. Cancer Research on Prevention and Treatment, 2022, 49(7): 667-674. DOI: 10.3971/j.issn.1000-8578.2022.21.1486

Citation:

PDF (17151 KB)

Research Hotspots and Frontiers of Immunotherapy for Prostate Cancer: A Visual Analysis

1.
The First School of Clinical Medicine, Lanzhou University, Lanzhou 730000, China
2.
Department of Urology, Gansu Provincial People's Hospital, Lanzhou 730000, China

Funding:

Gansu Provincial Science and Technology Program (Key R & D Program) 21YF5FA016

More Information

Corresponding author:
ZHOU Fenghai, E-mail: Zhoufengh@163.com
Received Date: December 20, 2021
Revised Date: February 27, 2022
Available Online: January 12, 2024

Graphical Abstract

Abstract

Abstract

Objective
To visualize and analyze the literature related to immunotherapy for prostate cancer published in the past 20 years through bibliometric analysis, and to explore the research progress and cutting-edge trends in this field.
Methods
The Web of Science core collection database was searched for literature related to immunotherapy for prostate cancer published from 2002 to 2021. CiteSpace and VOSviewer software were used to visualize and analyze the data and map the evolution of hotspots.
Results
There were 2 326 papers were finally included after excluding irrelevant studies. The field of immunotherapy for prostate cancer is in a rapid development stage; the United States has a great influence and China has a significant latecomer advantage; the National Cancer Institute, Memorial Sloan-Kettering Cancer Center and University of California, San Francisco are the main research institutions; American authors Gulley JL, Schlom J and Japanese author Itoh K have the highest number of publications. Currently, the main research hotspot is immune checkpoint inhibitors, and high-quality clinical trials are continuing to drive this process forward.
Conclusion
The exploration of novel immune pathways and the combination of different therapies will be the main trend of future research in immunotherapy for prostate cancer.
- Prostatic neoplasms,
- Immunotherapy,
- Immune checkpoint inhibitors,
- Bibliometrics,
- Visualization analysis

FullText(HTML)

Competing interests: The authors declare that they have no competing interests.

References (30)

References

[1]	Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249. doi: 10.3322/caac.21660
[2]	Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2): 115-132. doi: 10.3322/caac.21338
[3]	Merseburger AS, Alcaraz A, von Klot CA. Androgen deprivation therapy as backbone therapy in the management of prostate cancer[J]. Onco Targets Ther, 2016, 9: 7263-7274. doi: 10.2147/OTT.S117176
[4]	Xavier-Santos D, Padilha M, Fabiano GA, et al. Evidences and perspectives of the use of probiotics, prebiotics, synbiotics, and postbiotics as adjuvants for prevention and treatment of COVID-19: A bibliometric analysis and systematic review[J]. Trends Food Sci Technol, 2022, 120: 174-192. doi: 10.1016/j.tifs.2021.12.033
[5]	Wu M, Wang Y, Yan C, et al. Study on subclinical hypothyroidism in pregnancy: a bibliometric analysis via CiteSpace[J]. J Matern Fetal Neonatal Med, 2022, 35(3): 556-567. doi: 10.1080/14767058.2020.1729731
[6]	Cheng P, Tang H, Dong Y, et al. Knowledge Mapping of Research on Land Use Change and Food Security: A Visual Analysis Using CiteSpace and VOSviewer[J]. Int J Environ Res Public Health, 2021, 18(24): 13065. doi: 10.3390/ijerph182413065
[7]	陈悦, 陈超美, 刘则渊, 等. CiteSpace知识图谱的方法论功能[J]. 科学学研究, 2015, 33(2): 242-253. doi: 10.3969/j.issn.1003-2053.2015.02.009 Chen Y, Chen CM, Liu ZY, et al. The methodology function of CiteSpace mapping knowledge domains[J]. Ke Xue Xue Yan Jiu, 2015, 33(2): 242-253. doi: 10.3969/j.issn.1003-2053.2015.02.009
[8]	Zhou X, Yao Z, Bai H, et al. Treatment-related adverse events of PD-1 and PD-L1 inhibitor-based combination therapies in clinical trials: a systematic review and meta-analysis[J]. Lancet Oncol, 2021, 22(9): 1265-1274. doi: 10.1016/S1470-2045(21)00333-8
[9]	Kennedy LB, Salama AKS. A review of cancer immunotherapy toxicity[J]. CA Cancer J Clin, 2020, 70(2): 86-104. doi: 10.3322/caac.21596
[10]	Gulley JL, Borre M, Vogelzang NJ, et al. Phase Ⅲ Trial of PROSTVAC in Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer[J]. J Clin Oncol, 2019, 37(13): 1051-1061. doi: 10.1200/JCO.18.02031
[11]	Noguchi M, Arai G, Egawa S, et al. Mixed 20-peptide cancer vaccine in combination with docetaxel and dexamethasone for castration-resistant prostate cancer: a randomized phase Ⅱ trial[J]. Cancer Immunol Immunother, 2020, 69(5): 847-857. doi: 10.1007/s00262-020-02498-8
[12]	Bilusic M, McMahon S, Madan RA, et al. Phase Ⅰ study of a multitargeted recombinant Ad5 PSA/MUC-1/brachyury-based immunotherapy vaccine in patients with metastatic castration-resistant prostate cancer (mCRPC)[J]. J Immunother Cancer, 2021, 9(3): e002374. doi: 10.1136/jitc-2021-002374
[13]	Sartor O, Armstrong AJ, Ahaghotu C, et al. Survival of African-American and Caucasian men after sipuleucel-T immunotherapy: outcomes from the PROCEED registry[J]. Prostate Cancer Prostatic Dis, 2020, 23(3): 517-526. doi: 10.1038/s41391-020-0213-7
[14]	Sonpavde G, Di Lorenzo G, Higano CS, et al. The role of sipuleucel-T in therapy for castration-resistant prostate cancer: a critical analysis of the literature[J]. Eur Urol, 2012, 61(4): 639-647. doi: 10.1016/j.eururo.2011.10.027
[15]	Crawford ED, Petrylak DP, Higano CS, et al. Optimal timing of sipuleucel-T treatment in metastatic castration-resistant prostate cancer[J]. Can J Urol, 2015, 22(6): 8048-8055.
[16]	Seitter SJ, Sherry RM, Yang JC, et al. Impact of Prior Treatment on the Efficacy of Adoptive Transfer of Tumor-Infiltrating Lymphocytes in Patients with Metastatic Melanoma[J]. Clin Cancer Res, 2021, 27(19): 5289-5298. doi: 10.1158/1078-0432.CCR-21-1171
[17]	Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer[J]. N Engl J Med, 2010, 363(5): 411-422. doi: 10.1056/NEJMoa1001294
[18]	Small EJ, Schellhammer PF, Higano CS, et al. Placebo-controlled phaseⅢ trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer[J]. J Clin Oncol, 2006, 24(19): 3089-3094. doi: 10.1200/JCO.2005.04.5252
[19]	Higano CS, Schellhammer PF, Small EJ, et al. Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer[J]. Cancer, 2009, 115(16): 3670-3679. doi: 10.1002/cncr.24429
[20]	Kantoff PW, Schuetz TJ, Blumenstein BA, et al. Overall survival analysis of a phase Ⅱ randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer[J]. J Clin Oncol, 2010, 28(7): 1099-1105. doi: 10.1200/JCO.2009.25.0597
[21]	Bagchi S, Yuan R, Engleman EG. Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance[J]. Annu Rev Pathol, 2021, 16: 223-249. doi: 10.1146/annurev-pathol-042020-042741
[22]	Venkatachalam S, McFarland TR, Agarwal N, et al. Immune Checkpoint Inhibitors in Prostate Cancer[J]. Cancers (Basel), 2021, 13(9): 2187. doi: 10.3390/cancers13092187
[23]	Vitkin N, Nersesian S, Siemens DR, et al. The Tumor Immune Contexture of Prostate Cancer[J]. Front Immunol, 2019, 10: 603. doi: 10.3389/fimmu.2019.00603
[24]	Tsaur I, Brandt MP, Juengel E, et al. Immunotherapy in prostate cancer: new horizon of hurdles and hopes[J]. World J Urol, 2021, 39(5): 1387-1403. doi: 10.1007/s00345-020-03497-1
[25]	Sena LA, Denmeade SR, Antonarakis ES. Targeting the spectrum of immune checkpoints in prostate cancer[J]. Expert Rev Clin Pharmacol, 2021, 14(10): 1253-1266. doi: 10.1080/17512433.2021.1949287
[26]	Handa S, Hans B, Goel S, et al. Immunotherapy in prostate cancer: current state and future perspectives[J]. Ther Adv Urol, 2020, 12: 1756287220951404.
[27]	Abdul Sater H, Marté JL, Donahue RN, et al. Neoadjuvant PROSTVAC prior to radical prostatectomy enhances T-cell infiltration into the tumor immune microenvironment in men with prostate cancer[J]. J Immunother Cancer, 2020, 8(1): e000655. doi: 10.1136/jitc-2020-000655
[28]	Subudhi SK, Siddiqui BA, Aparicio AM, et al. Combined CTLA-4 and PD-L1 blockade in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer is associated with increased myeloid and neutrophil immune subsets in the bone microenvironment[J]. J Immunother Cancer, 2021, 9(10): e002919. doi: 10.1136/jitc-2021-002919
[29]	Pachynski RK, Morishima C, Szmulewitz R, et al. IL-7 expands lymphocyte populations and enhances immune responses to sipuleucel-T in patients with metastatic castration-resistant prostate cancer (mCRPC)[J]. J Immunother Cancer, 2021, 9(8): e002903.
[30]	Collins JM, Redman JM, Gulley JL. Combining vaccines and immune checkpoint inhibitors to prime, expand, and facilitate effective tumor immunotherapy[J]. Expert Rev Vaccines, 2018, 17(8): 697-705.

[1]	FANG Yuhang, ZHANG Chuchu, SUI Bailu, WANG Yan, WANG Runxi, CHEN Yu, YUAN Xinhe, YANG Hongjun, ZHANG Ying. Visualization Analysis of Research Hotspots and Trends in Field of Tumor Therapy Based on CiteSpace and VOSviewer[J]. Cancer Research on Prevention and Treatment, 2025, 52(4): 297-304. DOI: 10.3971/j.issn.1000-8578.2025.24.0959
[2]	WANG Jinming, NAN Peng, ZHAO Yanmeidai, HAO Shulan. Visual Analysis of Hotspots and Trends in Inflammation-Related Research in Colorectal Cancer[J]. Cancer Research on Prevention and Treatment, 2024, 51(11): 926-936. DOI: 10.3971/j.issn.1000-8578.2024.24.0091
[3]	FANG Yuhang, XIE Yi, YANG Shuhan, LIU Suying, FANG Liyuan, WANG Yan, WANG Runxi, ZHANG Ying. Visualization Analysis of Research Hotspots of Breast Cancer Microenvironment Based on CiteSpace and VOSviewer[J]. Cancer Research on Prevention and Treatment, 2024, 51(6): 448-454. DOI: 10.3971/j.issn.1000-8578.2024.24.0004
[4]	YANG Shuyan, ZHUANG Jinman, LIU Yuhang, ZHU Jinxiu, LIN Mengxin, HE Fei. Visual Analysis of Research on Lung Cancer Immunotherapy by Using CiteSpace[J]. Cancer Research on Prevention and Treatment, 2023, 50(1): 43-51. DOI: 10.3971/j.issn.1000-8578.2023.22.0495
[5]	GU Shanshan, XU Yun, WANG Jinghui. Current Status, Hot Spot Discovery and Integration Prospect of Cancer-related Fatigue Research at Home and Abroad Based on Bibliometric Visualization Map Analysis[J]. Cancer Research on Prevention and Treatment, 2022, 49(5): 418-426. DOI: 10.3971/j.issn.1000-8578.2022.21.0690
[6]	HONG Chen, PENG Xinyu, GUO Yin, WANG Jingsong. Research Progress of Exercise Intervention on Breast Cancer: A Visualization Analysis[J]. Cancer Research on Prevention and Treatment, 2022, 49(1): 32-39. DOI: 10.3971/j.issn.1000-8578.2022.21.0911
[7]	YANG Xi, CHU Yaojuan, CHEN Juanjuan, YANG Ting, LIU Chong, ZHANG Rui, DU Shuzhang. Visual Analysis and Focused Areas of Immunotherapy for Liver Cancer Based on Literature Data[J]. Cancer Research on Prevention and Treatment, 2021, 48(10): 963-969. DOI: 10.3971/j.issn.1000-8578.2021.21.0541
[8]	SUN Qiuyue, SUN Lichao, ZHANG Zhichun, PENG Liang, TIAN Gu. Trends in Research of Cancer Stem Cells: A Bibliometric Analysis Based on CiteSpace[J]. Cancer Research on Prevention and Treatment, 2021, 48(9): 839-845. DOI: 10.3971/j.issn.1000-8578.2021.21.0416
[9]	XIONG Senlin, ZHONG Xinyi, HUANG Qiuna, YANG Ying, ZHENG Weixin, QIU Hengjia. Visual Analysis of Chinese Literature on Cancer Screening in China Based on CiteSpace[J]. Cancer Research on Prevention and Treatment, 2020, 47(3): 198-203. DOI: 10.3971/j.issn.1000-8578.2020.19.0373
[10]	Huang Donglan, Xie Fei, Cen Dongzhi, Zhang Jiren. Clinical Research Essays on Breast Cancer Prognostic Genes from 2001 to 2010:a Bibliometric Analysis[J]. Cancer Research on Prevention and Treatment, 2012, 39(01): 91-94. DOI: 10.3971/j.issn.1000-8578.2012.01.024

Cited By

Cited by

Periodical cited type(4)

1.	王玉华，王海飞，李长建，常建琦，张春锋，李军. 改良前列腺尖部分离技术对腹腔镜前列腺癌根治术患者术后并发症及尿控功能的影响. 癌症进展. 2025(02): 181-184 .
2.	陈征，龚慧，刘东东，韩静. 肿瘤疫苗在前列腺癌治疗中的研究进展. 结直肠肛门外科. 2024(01): 8-11 .
3.	袁成钢，唐意涵，任瑞奇，马丁凌，李梦环，刘杰，魏茜茜，桑海明，王竞州，张君. Krüppel样因子7对前列腺癌细胞生物学行为的影响及分子机制. 中华肿瘤防治杂志. 2023(18): 1100-1109 .
4.	张婷，杨潇逸，潘黎姿，徐东紫，陈娟，欧阳昭连. 基于专利引文网络的神经母细胞瘤治疗领域技术前沿识别研究. 肿瘤防治研究. 2023(09): 866-872 . 本站查看

Other cited types(2)

Figures(6) / Tables(4)

Get Citation

PDF

XML

Article views (2136) PDF downloads (422) Cited by(6)

Turn off MathJax

Article Contents

Abstract

References

Research Hotspots and Frontiers of Immunotherapy for Prostate Cancer: A Visual Analysis